Multiple myeloma — a malignancy of clonal plasma cells within the bone marrow — is the second most common haematological cancer, accounting for approximately 10% of all blood cancers. Myeloma plasma cells produce abnormal immunoglobulin (the M-protein or paraprotein), infiltrate the marrow displacing normal haematopoiesis, and secrete osteoclast-activating factors causing the lytic bone lesions that are the hallmark of the disease. The clinical consequences are captured by the CRAB criteria: hypercalcaemia, Renal failure, Anaemia, and Bone lesions. Multiple myeloma requires haematology-oncology management — treatment with bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplantation in eligible patients has transformed outcomes — but the disease remains incurable in most cases. Constitutional homeopathy is strictly supportive: it can reduce treatment side effects, support energy and appetite, manage bone pain, and improve quality of life alongside oncology treatment, but it cannot replace chemotherapy, immunotherapy, or transplantation.
Diagnosis, Staging, and the CRAB Criteria
Multiple myeloma is diagnosed by the triad of clonal bone marrow plasma cells (greater than 10%), M-protein in serum or urine, and evidence of end-organ damage (CRAB criteria) or myeloma-defining events (MDEs). Investigations include serum protein electrophoresis and immunofixation, serum free light chain assay, 24-hour urine for Bence Jones protein, full blood count (normocytic anaemia), renal function and calcium, beta-2 microglobulin and LDH, bone marrow biopsy with cytogenetics and FISH, and whole-body low-dose CT or PET-CT for bone lesions. Staging by the Revised International Staging System (R-ISS) using beta-2 microglobulin, albumin, LDH, and cytogenetics guides prognosis and treatment intensity. Smouldering myeloma (asymptomatic with M-protein and elevated plasma cells but no end-organ damage) is monitored but not immediately treated unless high-risk.
Oncology Treatment — Chemotherapy and Stem Cell Transplantation
For transplant-eligible patients (generally under 70 with adequate organ function), induction therapy with bortezomib, lenalidomide, and dexamethasone (VRd) for four to six cycles, followed by high-dose melphalan and autologous stem cell transplantation (ASCT), followed by lenalidomide maintenance, has become the standard of care — achieving complete response in 40–50% of patients with overall survival exceeding five years in most series. For transplant-ineligible patients, VRd or Rd (lenalidomide-dexamethasone) combinations are used with daratumumab (an anti-CD38 monoclonal antibody) increasingly added. Relapsed or refractory myeloma is treated with pomalidomide, carfilzomib, isatuximab, belantamab mafodotin, or idecabtagene vicleucel (CAR-T). All treatment decisions must be made by a haematologist-oncologist specialising in myeloma — homeopathy cannot replace any of these interventions.
Constitutional Homeopathic Supportive Care
Constitutional homeopathy for multiple myeloma focuses on supporting the patient through the rigours of chemotherapy and transplantation — reducing nausea, improving appetite and energy, managing bone pain, supporting immune recovery post-transplant, and addressing the profound anxiety and grief that accompany a myeloma diagnosis. Homeopathic treatment also addresses the constitutional predisposition and miasmatic background. The constitutional prescription must account for the individual symptom pattern — the nature of bone pain (aching, boring, burning), the haematological profile (anaemia-dominant, hypercalcaemia-dominant), the kidney involvement, and the emotional constitution (the fearful type, the despairing type, the still-fighting type).
Key Homeopathic Remedies for Multiple Myeloma Supportive Care
Phosphorus addresses the haemorrhagic, sympathetic, thin, warm-blooded constitutional type — easy bruising, bleeding tendency from thrombocytopaenia, profound anaemia with pallor, burning bone pain, and great weakness. Phosphorus also supports liver and kidney function during intensive chemotherapy. Arsenicum Album suits the anxious, restless, midnight-aggravated myeloma patient — profound prostration with burning pains relieved by warmth, marked cachexia, nausea and vomiting from chemotherapy, and existential anxiety about prognosis. Calcarea Phosphorica supports bone remodelling and addresses the boring bone pain of lytic lesions — particularly useful in the pale, cold, thin, growth-retarded or depleted constitutional type with weak bones and slow recovery. China Officinalis (Cinchona) addresses the profound debility, sweating, and weakness from anaemia and haemorrhage — periodic exhaustion with ringing in the ears, marked sensitivity to touch, and recovery of vitality between treatment cycles.
Key Points at a Glance
Multiple myeloma requires haematologist-oncologist management — bortezomib, lenalidomide, dexamethasone, and ASCT are the treatment backbone
Bone pain, new fractures, or sudden back pain in a myeloma patient may indicate a pathological fracture — immediate medical review is essential
Renal impairment in myeloma is often from light chain cast nephropathy — adequate hydration and prompt treatment are critical to preserve kidney function
Phosphorus suits the haemorrhagic, anaemic, sympathetic type; Arsenicum Album the anxious, restless, cachexic type with burning pains
Homeopathy in myeloma is strictly supportive — it can reduce side effects and improve quality of life but cannot replace chemotherapy or stem cell transplantation
Seeking constitutional supportive care alongside myeloma oncology treatment?
Dr. Meera Thakur offers constitutional homeopathic treatment for multiple myeloma at HealthKunj Clinics, Kharadi, Pune — strictly supportive and always coordinated with your haematology-oncology team.
Book Free Consultation
Dr. Meera Thakur
BHMS · HealthKunj Clinics, Kharadi, Pune
Dr. Meera has 15+ years of experience in individualised homeopathic practice with a special interest in women's hormonal health, skin disorders, and paediatric care.
Read full profile